本研究旨在评估一种研究性 RAS(ON) 抑制剂以单药治疗或与化疗联合使用，相较於单独使用标准治疗（SOC）化疗的安全性与疗效。
适应症：Pancreatic Cancer、Pancreatic Cancer Metastatic、PDAC、PDAC - Pancreatic Ductal Adenocarcinoma、Pancreatic Ductal Adenocarcinoma (PDAC)、Pancreatic Adenocarcinoma Metastatic、Pancreatic Adenocarcinoma、Pancreatic Adenosquamous Carcinoma
入组条件
纳入标准
- At least 18 years old and has provided informed consent.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Histologically or cytologically confirmed pancreatic adenocarcinoma.
- Diagnosis of metastatic disease ≤ 6 weeks prior to informed consent.
- Documented RAS mutation status, either mutant or wild-type.
- Measurable disease per RECIST v1.1.
- Adequate organ function (bone marrow, liver, kidney, coagulation).
- Able to take oral medications.
排除标准
- Prior treatment with systemic anticancer therapy in metastatic setting or prior RAS-targeted therapy in any treatment setting.
- Active or known history of untreated central nervous system metastatic disease.
- Any conditions that may affect the ability to take or absorb study drug.
- Major surgery within 28 days prior to randomization.
- Patient is unable or unwilling to comply with protocol-required study visits or procedures.
入组条件维持 ClinicalTrials.gov 原始英文登记资料，实际入组资格以研究团队的正式评估与受试者知情同意书为准。资料来源：ClinicalTrials.gov，每两周自动更新，最后同步：2026年10月8日。